Highlights

• Dimerix acquired DMX-652, an oral once-daily USP30 inhibitor for acute kidney injury, from Mission Therapeutics for US$5 million upfront plus potential milestone payments of up to US$287 million.

• The company secured a US composition-of-matter patent for DMX-652 extending protection to April 2043.

• Dimerix’s ACTION3 Phase 3 trial for DMX-200 in focal segmental glomerulosclerosis (FSGS) is fully recruited with 286 patients enrolled.

• Cash stood at A$26.6 million at 31 March 2026, supported by potential additional funding from licensing proceeds and financing arrangements.

• Dimerix shares traded at A$0.25 on 28 July 2026, rising A$0.005 or 2.04% during the session.

Dimerix Limited (ASX:DXB) has expanded its clinical pipeline by acquiring DMX-652, a Phase 2-ready acute kidney injury treatment candidate, adding a second renal-focused asset alongside its existing DMX-200 program.

The acquisition changes the structure of the company’s development strategy, which previously depended largely on the outcome of its ACTION3 Phase 3 trial evaluating DMX-200 in focal segmental glomerulosclerosis.

The addition of DMX-652 provides another potential development pathway, supported by human safety data, an FDA-cleared Phase 2 protocol and long-term patent protection.

However, the company remains dependent on clinical execution, regulatory progress and funding availability as it advances two kidney disease programs.

DMX-652 Acquisition Adds New Development Opportunity

On 17 July 2026, Dimerix acquired global rights to DMX-652 from UK-based Mission Therapeutics.

The agreement includes:

  • US$5 million upfront payment.
  • Up to US$47 million in development milestones.
  • Up to US$40 million upon regulatory approval.
  • Up to US$25 million linked to a second indication.
  • Up to US$175 million in sales milestones.

The total potential milestone value is approximately US$287 million.

Dimerix will also pay royalties ranging between 8% and 10% on direct sales, or 2.5% to 5% where the product is commercialised through a sublicense partner.

The transaction structure limits upfront capital requirements while providing access to a clinical-stage asset.

US Patent Extends DMX-652 Protection to 2043

A key development following the acquisition was the granting of a US composition-of-matter patent covering DMX-652.

The patent protects the molecule itself rather than only a specific application, providing a broader form of intellectual property protection.

The patent includes 677 days of patent term adjustment due to delays in the US patent examination process, extending protection until 11 April 2043.

Long patent duration is important for clinical-stage pharmaceutical assets because commercialisation timelines can extend over several years before revenue generation begins.

DMX-652 Targets Acute Kidney Injury

DMX-652 is an oral once-daily USP30 inhibitor designed to regulate mitochondrial quality control.

The treatment works by inhibiting USP30, an enzyme involved in regulating mitophagy, the process through which cells remove damaged mitochondria.

A Phase 1 study involving 85 healthy volunteers evaluated DMX-652 doses up to 200 mg and 14 days of daily dosing at 100 mg.

The study reported tolerability without drug-related serious adverse events and did not identify a maximum tolerated dose.

The FDA has cleared the Phase 2 trial protocol, which is planned as a placebo-controlled study involving approximately 160 cardiac surgery patients.

The primary endpoint is the incidence of acute kidney injury seven days after surgery.

ACTION3 Phase 3 Trial Remains Core Value Driver

Despite pipeline expansion, DMX-200 remains the most important near-term clinical program for Dimerix.

DMX-200 combines repagermanium, a CCR2 antagonist, with an angiotensin II receptor blocker to target inflammatory pathways involved in kidney damage.

The therapy is being evaluated in focal segmental glomerulosclerosis (FSGS), a rare kidney disease associated with progressive scarring of kidney filtering units.

The ACTION3 Phase 3 trial has completed recruitment, with 286 patients enrolled.

The study has passed a blinded futility assessment, allowing the trial to continue.

However, passing a futility assessment does not confirm efficacy. Final clinical outcomes remain dependent on the trial’s primary endpoint and long-term data.

Licensing Strategy Supports Commercialisation Approach

Dimerix has historically focused on licensing partnerships rather than direct commercialisation.

The company has entered multiple licensing agreements for DMX-200 across different geographic regions.

The agreements include potential milestone payments and royalties across markets including:

  • United States.
  • Europe.
  • Canada.
  • Australia and New Zealand.
  • Greater China.
  • South Korea.
  • Southeast Asia.
  • Japan.
  • Gulf Cooperation Council countries and Iraq.

The company has reported potential aggregate consideration of approximately A$1.9 billion across licensing arrangements, with more than A$80 million received to date.

DMX-652 fits within this strategy by adding another kidney-focused asset that could potentially attract future licensing partners.

Financial Position and Funding Outlook

Dimerix reported cash of A$26.6 million as at 31 March 2026.

The company also secured additional funding support through:

  • A potential licensing upfront payment from Everest Medicines.
  • A related-party A$10 million non-dilutive loan facility.

The loan facility carries:

  • 10% annual compounding interest.
  • Repayment due in January 2028.
  • A requirement to share 30% of DMX-200 milestone payments, capped at twice the drawn amount.

Dimerix was also negotiating additional financing support.

The company stated that available funding would support completion of ACTION3 and initiation of the DMX-652 Phase 2 study, subject to completion of relevant agreements.

Why the Development Matters

The DMX-652 acquisition addresses a key weakness in Dimerix’s previous structure: reliance on a single clinical asset.

Adding a second renal program provides pipeline diversification while allowing the company to leverage existing expertise and potential commercial relationships.

The long patent life of DMX-652 also improves the potential commercial timeframe if clinical development succeeds.

However, diversification does not remove clinical risk. Both programs remain dependent on successful trials and regulatory outcomes.

Potential Growth Catalysts

• Completion of definitive documentation for funding facilities.

• Receipt of the expected Everest Medicines upfront payment.

• Initiation of the DMX-652 Phase 2 clinical study.

• Progress updates from the ACTION3 Phase 3 trial.

• Potential future licensing agreements for DMX-652.

Risks and Challenges

Clinical risk remains the largest factor for Dimerix.

ACTION3 passing a futility assessment allows the trial to continue but does not establish treatment effectiveness. Final results will determine the value of DMX-200.

Funding risk has also increased as Dimerix expands from one clinical program to two.

While the company has secured non-dilutive funding options, these arrangements include financial costs and future obligations linked to milestone payments.

DMX-652 also remains an early-stage asset. Phase 2 readiness does not guarantee successful clinical outcomes or regulatory approval.

What Investors Should Watch Next

Key developments include:

• June 2026 quarterly cash flow update.

• Confirmation of licensing receipts and financing arrangements.

• DMX-652 Phase 2 preparation and site activation.

• ACTION3 trial progress and future data milestones.

• Potential commercial partnerships.

Conclusion

Dimerix has strengthened its pipeline through the acquisition of DMX-652, adding a Phase 2-ready kidney asset with patent protection extending into 2043.

The transaction provides additional strategic options while the company continues advancing its core DMX-200 Phase 3 program.

The key challenge remains execution. Clinical outcomes from ACTION3, successful development of DMX-652 and delivery of planned funding will determine whether the expanded pipeline translates into long-term value.